By Nana O 
A groundbreaking study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has revealed that monitoring minuscule fragments of DNA shed by dying tumor cells in the bloodstream could accurately predict the recurrence of skin cancer, particularly melanoma. This innovative approach holds significant potential for revolutionizing how oncologists manage patients with stage III melanoma, a particularly aggressive form of the disease.
Early Detection and Prognostic Power of Circulating Tumor DNA
The study, published on April 15 in the esteemed journal The Lancet Oncology, analyzed nearly 600 men and women who had previously participated in a clinical trial for stage III melanoma. The findings demonstrated a compelling correlation between the presence of circulating tumor DNA (ctDNA) and the likelihood of cancer returning. Approximately 80% of stage III melanoma patients who had detectable levels of ctDNA before commencing treatment to suppress their tumors subsequently experienced recurrence.
This detection of ctDNA prior to treatment acted as a potent prognostic indicator. The research indicated that the disease returned more than four times faster in patients with detectable ctDNA compared to those with no detectable levels of this biomarker. Furthermore, the study established a dose-response relationship: the higher the levels of ctDNA detected, the more rapid the cancer’s return.
"Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," stated Mahrukh Syeda, MS, the study’s lead author and a research scientist in the Ronald O. Perlman Department of Dermatology at NYU Grossman School of Medicine. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions."
Monitoring Treatment Efficacy and Identifying Worsening Disease
Beyond predicting initial recurrence, the study also highlighted the utility of ctDNA in monitoring treatment progress. The research team observed that nearly all patients with detectable ctDNA levels at various points during treatment – specifically at three, six, nine, or twelve months – experienced melanoma recurrence. This suggests that ctDNA can serve as an early warning system, indicating that the disease might be worsening even if not yet apparent through conventional imaging methods.
The implications of this finding are profound, particularly for stage III melanoma. In this stage, tumor cells have already spread from the primary skin lesion to nearby lymph nodes. Following the surgical removal of these lymph nodes, recurrence can be notoriously difficult to detect using standard imaging techniques such as X-rays and CT scans. The emergence of ctDNA as a sensitive biomarker offers a promising solution to this diagnostic challenge, enabling earlier identification of disease progression.
"Swiftly tracking treatment progress and the ability to spot signs of cancer growth could be helpful in a disease as dangerous as melanoma, which is notoriously difficult to treat once it spreads to other body parts," Syeda emphasized. "Early feedback from a ctDNA analysis might save lives."
The Science Behind Circulating Tumor DNA Detection
The ctDNA method functions by targeting specific, common mutations found in the genetic code of melanoma cells. As tumor cells break down, these mutated DNA fragments are released into the surrounding bloodstream. By analyzing blood samples, researchers can detect and quantify these ctDNA fragments, providing a real-time snapshot of the tumor’s presence and activity within the body.
This innovative approach builds upon previous research that has demonstrated the efficacy of ctDNA tests in tracing the progression of other cancers, including colorectal and breast cancers. Notably, in 2021, the same research team published findings indicating that higher ctDNA levels in patients with stage IV melanoma (which has spread throughout the body) were associated with lower survival rates. They also discovered that changes in ctDNA measurements during treatment could effectively predict survival outcomes.
The current investigation represents the largest study to date assessing ctDNA as a predictor for recurrence specifically in stage III melanoma patients. The comprehensive nature of the study, involving blood samples from a diverse cohort across Europe, North America, and Australia, enhances the robustness of its findings.
Rigorous Methodology and Comparative Efficacy
The study’s statistical analysis was meticulously designed to account for various factors that could influence cancer recurrence, including sex, age, and the type of therapy received. This ensured that the observed correlation between ctDNA levels and recurrence was attributable to the biomarker itself, rather than confounding variables.
A significant finding from the research was the comparative efficacy of ctDNA assessment. The results indicated that measuring ctDNA levels was as effective, if not superior, to other experimental tests that examine the tumor itself. These include methods that assess immune activity within a group of cancer cells, suggesting that ctDNA offers a more direct and potentially more sensitive measure of the disease.
"Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," explained Dr. David Polsky, MD, PhD, the study’s senior author and a distinguished dermatologist at NYU Langone Health. Dr. Polsky holds the prestigious Alfred W. Kopf, M.D., Professor of Dermatologic Oncology position in the Ronald O. Perelman Department of Dermatology.
Future Directions and Clinical Translation
While the study presents a significant leap forward, the researchers acknowledge that the ctDNA test is not yet infallible. Dr. Polsky cautioned that in some instances, cancer recurred despite patients receiving a negative ctDNA test result prior to initiating therapy. This underscores the ongoing need for refinement and further validation of the technology.
To address this limitation, the research team plans to focus on improving the sensitivity of their ctDNA test. Furthermore, they intend to explore the clinical utility of using this biomarker to guide treatment decisions. The ultimate goal is to determine whether proactive treatment adjustments based on ctDNA monitoring can indeed lead to improved patient survival rates and enhanced quality of life.
The research was supported by funding from Novartis Pharmaceuticals Corporation. Dr. Polsky has disclosed advisory board memberships and received honoraria and research contracts from various pharmaceutical companies, including Novartis and Merck. These relationships are managed in accordance with NYU Langone Health’s policies.
The study involved a multidisciplinary team of investigators. In addition to Syeda and Polsky, NYU Langone Health researchers Jennifer Wiggins-Crosby, PhD, and Saim Ali, BA, were instrumental. Collaborators from leading institutions worldwide included Georgina Long, MD, PhD (University of Sydney, Australia); James Garrett, PhD (Novartis Pharmaceuticals Corporation, USA); Victoria Atkinson, MD (University of Queensland, Australia); Mario Santinami, MD (National Cancer Institute of Milan, Italy); Dirk Schadendorf, MD (University of Duisburg-Essen, Germany); Axel Hauschild, MD (University Hospital, Campus Kiel, Germany); Michael Millward, MD (University of Western Australia, Australia); Mario Mandala, MD (University of Perugia, Italy); Vanna Chiarion-Sileni, MD (Veneto Institute of Oncology, Italy); Michael Smylie, MD (Cross Cancer Institute, Canada); Georgy Manikhas, MD (St. Petersburg Oncology Hospital, Russia); Reinhard Dummer, MD (University Hospital Zurich Skin Cancer Center, Switzerland); Sachin Bajirao Adnaik, PhD (Novartis Healthcare Pvt. Ltd., India); and Monique Tan, MD, MPH, and Maya Dajee, PhD (Novartis Pharmaceuticals, USA).
Broader Implications for Melanoma Management
The widespread adoption of ctDNA monitoring for stage III melanoma could usher in a new era of personalized and proactive cancer care. By providing oncologists with a more precise and timely assessment of disease status, this technology has the potential to:
- Optimize Treatment Strategies: Identify patients who may benefit from more aggressive or alternative therapies early on, potentially improving outcomes.
- Reduce Unnecessary Treatments: For patients showing a complete response with undetectable ctDNA, it might be possible to de-escalate treatment intensity, minimizing side effects and improving quality of life.
- Facilitate Earlier Intervention: Promptly detecting recurrence allows for earlier intervention, which is often associated with better prognosis in cancer.
- Enhance Clinical Trial Design: ctDNA could serve as a valuable biomarker in future clinical trials, enabling more efficient patient stratification and outcome assessment.
While challenges remain in terms of test standardization, cost-effectiveness, and integration into routine clinical workflows, the findings from this study represent a significant stride towards making ctDNA-based monitoring a standard component of melanoma management. The promise of detecting cancer recurrence earlier and more reliably could fundamentally alter the trajectory of this challenging disease for countless patients.